ReviewCNS drug reviews
Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
Review in CNS drug reviews. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 80 citations in OpenAlex.
- 5-HT Receptors and the Development of New Antidepressants.International journal of molecular sciences · 2021Review
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacological reviews · 2021Review
- Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain.Frontiers in pharmacology · 2020Article
- Effect of the 5-HTInternational journal of molecular sciences · 2019Article
- Article
- 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Synthesis and Structure-Activity Relationships of Tool Compounds Based on WAY163909, a 5-HTACS chemical neuroscience · 2017Article
- A short history of the 5-HTPsychopharmacology · 2017Review
- Theranostic Biomarkers for Schizophrenia.International journal of molecular sciences · 2017Review
- Review
- Imaging evaluation of 5HT2C agonists, [(11)C]WAY-163909 and [(11)C]vabicaserin, formed by Pictet-Spengler cyclization.Journal of medicinal chemistry · 2014Article
- Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.ACS chemical neuroscience · 2013Article
- Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.ACS medicinal chemistry letters · 2011Article
- Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.Neuropharmacology · 2011Article
- Marine indole alkaloids: potential new drug leads for the control of depression and anxiety.Chemical reviews · 2010Review
- HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.ChemMedChem · 2010Article
- Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity.The European journal of neuroscience · 2009Article
- PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009Article
- WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.Psychopharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5-HT(2C) receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT(2C) receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.